A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina

Vasospastic Angina Clinical Trial

— STELLA  

Official title:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Pletaal(Cilostazol) in Subjects With Vasospastic Angina

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02087007
• Other study ID #: 021-KOA-1301i
• Status: Completed
• Phase: Phase 3
• First received: February 17, 2014
• Last updated: May 1, 2017
• Start date: November 2013
• Est. completion date: July 2015

Study information

• Verified date: May 2017
• Source: Korea Otsuka Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be conducted in accordance with the local regulation of New Drug Application. Overall duration of this trial will be 3 years after approval of KFDA.

Each subject will participate around 7 weeks, which include the 2 weeks Amlodipine run-in period, 4 weeks double blind period and 1 week safety follow up period

Description:

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel group, Therapeutic confirmatory Study.

The subject who has at least one episode of chest pain weekly and at least two episodes of chest pain during last week despite Amlodipine 5mg qd taking during 2 weeks will have treatment of Pletaal(Cilostazol) or Placebo for 4 weeks. Pletaal(Cilostazol) is taken 100mg oral tablets bid during 2 weeks after dosing of Pletaal(Cilostazol) 50mg oral tablets bid during 2 weeks. Placebo of Pletaal(Cilostazol) is used as the control medication.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 79 Years

Eligibility

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study :

1. Male or female 20 or over the age of 20 and under the age of 80.

2. Patients showing angina attack even while resting during the screening, diagnosed with vasospastic angina within the previous 3 months by meeting at least one of the 3 definitions, and accompanying insignificant (stenosis rate <50%) coronary artery disease documented by coronary angiography within the last 3 months [temporary antispastic agents (monotherapies or a combination of Verapamil and Nitroglycerin, anticoagulants) for coronary angiography are allowed]

• Chest pain accompanied by at least 2 temporary, closely located ST elevations or depressions of 0.1mV or greater in the absence of ergonovine provoked coronary angiography.

• Positive Intracoronary (IC) or Intravenous (IV) Ergonovine provocation test; ischemic ECG change accompanied by chest pain and spasm reducing the coronary diameter by 90% or more (at least 2 temporary, closely located ST elevations or depressions of 0.1mV or greater on 12-lead ECG)

3. Patients who reported at least 1 episode of chest pain in a week during amlodipine run-in period and at least 2 episodes in the final week.

4. Women who had been menopausal or sterile for at least 1 year, or women of childbearing potential who agree to practice a contraceptive measure throughout the clinical trial (e.g., hormonal contraceptives, intrauterine devices, condom + spermicidal agents, diaphragm + spermicidal agents, and partner's infertility)

5. Subjects who signed a written agreement indicating that they were given full explanations of the clinical trial and are willing to participate in the clinical trial.

Subjects presenting with any of the following will not be included in the study:

1. Subjects who used Cilostazol within 3 months before the screening visit

2. Subjects who used antiplatelet drugs, including Aspirin, Clopidogrel, Ticlopidine and Sarpogrelate, or PDE3 inhibitors of the same class as Cilostazol, such as Amrinone, Milrinone and Enoximone, after the initiation of the amlodipine run-in period

3. Subjects who used oral anticoagulants, such as warfarin, within 1 months prior to the screening visit

4. Subjects who used any of the following drugs within 1 week prior to the screening visit

• CCBs apart from amlodipine

• Beta-blockers or alpha-blockers

• Oral nitrate, excluding nitroglycerin sublingual tablet, Nicorandil

• Vitamin E preparations

• Estrogens

5. History of myocardial infarction or with myocardial infarction mediated by vasospastic angina at the time of screening

6. History of a life-threatening vasospastic event (e.g., ventricular tachycardia, atrial fibrillation or syncope)

7. History of stroke, intracranial hemorrhage or transient ischemic attack (TIA)

8. Hemorrhage (hemophilia, capillary fragility, upper gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.) or such predisposition (active peptic ulcer, hemorrhage suspected at Cilostazol administration for surgical wound within the last 3 months, proliferative diabetic retinopathy)

9. History of hypersensitivity to the ingredients of Cilostazol, amlodipine, dihydropyridines such as nitroglycerine, and nitrates

10. Severe aortic stenosis

11. History of shock

12. Hypotension with systolic pressure of below 90mmHg at screening

13. Severe anemia with hemoglobin 6.5g/dl or below at screening

14. History of glaucoma

15. ST change abnormality not interpretable on ECG at screening

16. Congestive heart failure with left ventricular ejection fraction <40% on echocardiography at screening or within the last 3 months

17. Atrial fibrillation or beyond moderate valvular heart disease

18. Left main coronary spasm suspected or confirmed by coronary angiography or ergonovine provoked coronary angiography

19. History of coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI)

20. Heart rate >100 bpm at screening via vital sign: tachycardia

21. Uncontrolled hypertension with systolic pressure = 160 mmHg or diastolic pressure = 100 mmHg at screening

22. Creatinine level = 1.5 mg/dL at screening

23. AST or ALT > x3 ULN(Upper Limit of Normal) at screening

24. Platelet count < 100,000mm3 at screening

25. QT prolongation of QTcB > 450 msec in male and QTcB>470 msec in female subjects at screening

26. Women of childbearing potential with positive pregnancy test at screening

27. Women who did not agree to practice a contraceptive measure, pregnant or lactating women

28. Drug compliance of less than 80% during 2-week amlodipine run-in period

29. Subjects otherwise judged by the investigator to be inappropriate for inclusion in the trial

30. Subjects who used another investigational products within 2 months prior to the randomization

Related Conditions & MeSH terms

• Angina Pectoris
• Angina Pectoris, Variant
• Vasospastic Angina

Intervention

Drug:
• Cilostazol
100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks
• placebo
100mg oral placebo tablets bid during 2 weeks after dosing of 50mg oral placebo tablets bid during 2 weeks

Locations

Country	Name	City	State
Korea, Republic of	Yangsan Busan University Hospital	Busan

Sponsors (1)

Lead Sponsor	Collaborator
Korea Otsuka Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Chest Pain Frequency	Change of the chest pain frequency on the final a week after IP dosing from a week before IP dosing	Baseline and Week 4
Secondary	Percent change of the chest pain frequency	Percent change of the chest pain frequency on the final a week after IP dosing from a week before IP dosing	Baseline and Week 4
Secondary	Proportion of subjects without chest pain	Proportion of subjects without chest pain on the final a week after IP dosing	4 weeks
Secondary	total chest pain intensity	Change of the total pain intensity on the final a week after IP dosing from a week before IP dosing	Baseline and Week 4
Secondary	average pain intensity(the total pain intensity/the number of pain)	Change of the average pain intensity(the total pain intensity/the number of pain) on the final a week after IP dosing from a week before IP dosing	Baseline and Week 4
Secondary	total nitroglycerin sublingual consumption	Change of the total nitroglycerin sublingual consumption of the final a week after IP dosing from a week before IP dosing	Baseline and Week 4